Member Info for researcher1

well I'm glad you've done well with him robbie - take a look at some of his darlings though: Concepta (now myhealthchecked) tipped at 18p - later hit 1p; Fox Marble tipped at 18, now he's encouraging top-ups at 2p, Stanley Gibbons, tipped at £1.10 (!!) etc etc. I would agree his bear cases are much better, but as I refuse to short shares (though I'm thinking about Tesla, I must admit) they don't interest me except as shares to avoid. Doing your own research is obviously the best method.

totally with you there guys - I have found TW to be one of the worst pundits around, but his scattergun high-risk approach inevitably throws up some high performers. Even with his abundant lack of knowledge (and research) he can still recognise the opportunity at SBTX - speaks volumes.

thanks Phoenix, I've seen those, and also an earlier interview with SA, and I agree this trial is non-binary, though we await percentage efficacies. I may decide not to trade, depending on market sentiment over the summer. I'm also heavily in Angle, so interesting times ahead.

well played Phoenix - my holding is similar to yours - a large clump of cheap ones at 18p, and lots bought over the past fortnight at under 30 whenever possible. Do you have a Sell or top slice target? I may sell half at 60p on the trial rise, and look to put it all back in when it drifts back to 45 ish to await the Croda auction. £1 for Christmas!

putting my slices back in today - they would only give me 12.35 to buy - everyone else seems to be able to get 12.12... anyway what's a couple of pence between friends...?

it did reach 36 at one point belgrano - do you have a target? with good trial feedback we should be seeing 50p in May, that doubles after Croda 'auction', and THEN there is clear blue sky.....

perhaps you are regretting your 'sell now, buy back cheaper" strategy?

£5B isn't really on a timeline crypt, as Angle would likely be bought out before then - the best guidance for a near-term target are AN's options around the £4 mark, based on performance. The share will likely double on FDA green light, so a lot will depend upon news/reaction leading up to that moment. £1 before, £2 after FDA is realistic, then up to £4 over the following year as the big boys sniff around...

pre-tested treatment, will begin to make half the MCAP per year beginning summer 2021 - and then there's Croda. This is a silly price, make use of it.

chill, hooray - the big action is to come later....

Remember those dark days of 38p, with Jupiter selling every last share they had at whatever anyone would give for them??
Here we are a mere month later, the SP twice that price, fifth in the leader board, with huge news still to come. Greetings 2021!

don't take much out testtest - see my latest post on predicted SP movement....
always a chance it will fade slightly for a few days, but the prize is just too huge to be ignored by the investment community.

so with today's demonstration of excellence, leading to inevitable world domination, any thoughts on where the SP will be prior to FDA result?
I predicted 70 -80p but I notice we are already there; with two bits of news to come soon (ovarian study; clinics) and bags of expectation, can the SP reach £1, in preparation for a quick hike to £2 on FDA confirmation?

apologies - I see the original date. Lucky you got in when you did!

you have the wrong board test-test, the SPs are all wrong.

I'd like to buy a bunch more here but the spread is off-putting....

not sure they can add this to the submission at this point Sangi, though one would hope the FDA would notice it. Angle's MCAP is tiny compared to what AN has termed "the magnitude of the opportunity".....

stay calm Zeppo, remember this is only the preamble....

it is such a powerful endorsement - I wonder if all CellSearch's US shareholders will start jumping in here?

one thing is for sure - we are going to have to worry about CGT